Mark Leonard Singleton - 21 Mar 2025 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
SVP & CFO
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
21 Mar 2025
Transactions value $
$0
Form type
4
Date filed
21 Mar 2025, 17:24
Previous filing
20 Feb 2025
Next filing
25 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise $0 +18.6K +15.68% $0.00 137K 21 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -18.6K -50% $0.00 18.6K 21 Mar 2025 Class A Common Stock 18.6K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The original grant of 74,500 RSUs vests in four approximately equal annual installments that began on March 21, 2023.